Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 21, 2019

Primary Completion Date

April 2, 2020

Study Completion Date

April 2, 2020

Conditions
Obstructive Sleep Apnea
Interventions
DRUG

TAK-925

TAK-925 IV infusion

DRUG

Placebo

TAK-925 placebo-matching IV infusion

Trial Locations (18)

20815

"Helene A. Emsellem, MD PC trading as The Center for Sleep & Wake Disorders", Chevy Chase

29201

Bogan Sleep Consultants, LLC, Columbia

30281

SleepCare Research Institute, Inc. d/b/a Clinical Research Institute, Stockbridge

30342

NeuroTrials Research, Inc., Atlanta

32216

Jacksonville Center for Clinical Research, Jacksonville

32789

Florida Pulmonary Research Institute, LLC, Winter Park

33009

MD Clinical, Hallandale

33024

Research Centers of America, Hollywood

34741

Pulmonary Disease Specialists, PA, d/b/a PDS Research, Kissimmee

35007

Wright Clinical Research, Alabaster

44195

The Cleveland Clinic Foundation, Cleveland

45212

CTI Clinical Trial and Consulting Services, Cincinnati

72211

Preferred Research Partners, Inc., Little Rock

78229

Sleep Therapy & Research Center, San Antonio

80918

Delta Waves Sleep Disorders and Research Center, Colorado Springs

85306

Pulmonary Associates Clinical Trials, Glendale

92103

Pacific Research Network, Inc, San Diego

94063

Stanford School of Medicine, Redwood City

All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT04091425 - Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP) | Biotech Hunter | Biotech Hunter